# Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

> **NCT00922272** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 92 (actual)

## Conditions studied

- Schizophrenia and Predominant Negative Symptoms

## Interventions

- **DRUG:** SPD489 (lisdexamfetamine dimesylate)
- **DRUG:** Placebo matching SPD489 (lisdexamfetamine dimesylate)

## Key facts

- **NCT ID:** NCT00922272
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-14
- **Primary completion:** 2011-01-20
- **Final completion:** 2011-01-20
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922272, "Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00922272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*